ArticleAmerican journal of translational research2026
Molecular mechanisms of Buyang Huanwu Decoction in improving Diabetic kidney disease based on network pharmacology and experimental validation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn Chinese medicine, Buyang Huanwu Decoction (BHD) has shown efficacy in improving renal function. Nevertheless, its specific pharmacological mechanisms in treating diabetic kidney disease (DKD) have not yet been fully elucidated.
methodsIn this study, the active ingredients of BHD were first identified using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, with their potential targets predicted via SwissTargetPrediction and confirmed in TCMSP. DKD-related targets were obtained from the GeneCards and DisGeNET databases. A protein-protein interaction (PPI) network was then constructed with the shared targets using the STRING database. Functional annotation was performed through Gene Ontology (GO) analysis on Metascape, while pathway enrichment analysis was conducted using the Kyoto Encyclopedia of Genes and Genomes (KEGG) via the ClueGO plugin in Cytoscape. Finally, in vivo experiments were performed to validate the mechanisms of BHD.
resultsA total of 634 active ingredients were identified in BHD. Among them, 222 corresponded to potential drug targets, and 3,665 disease targets related to DKD were obtained. Based on their intersection, a pharmacological network comprising 156 genes was constructed. Sixteen active ingredients were found to be involved in alleviating renal injury in DKD. GO and KEGG enrichment analyses revealed that the effects of BHD are primarily mediated through pathways related to inflammatory responses, lipid metabolism, and anti-oxidation, including the IL-17 and TNF signaling pathways. Animal experiments further confirmed that BHD alleviates renal fibrosis by inhibiting oxidative stress and inflammation, mechanisms that involve the Nrf2/HO-1 and NF-κB signaling pathways.
conclusionsBHD ameliorates DKD primarily through antioxidative, anti-inflammatory, and anti-fibrotic mechanisms, ultimately reducing proteinuria and preserving renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.